Hi-Tech Pharmacal (HITK) Shares Dip Midday Following Needham Downgrade
Tweet
Share
E-mailGet Alerts HITK Hot Sheet
Price: $43.49 --0%
Rating Summary:
1 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 13 | New: 20
Rating Summary:
1 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 13 | New: 20
Join SI Premium – FREE
Shares of Hi-Tech Pharmacal (NASDAQ: HITK) edged lower during Monday's afternoon session following a mid-day downgrade from Needham & Company.
The firm now rates Hi-Tech shares a Hold, down from Buy previously.
The stock is down more than 8 percent this afternoon despite strong Q2 results from the company this morning.
For an analyst ratings summary and ratings history on Hi Tech Pharmacal click here. For more ratings news on Hi Tech Pharmacal click here.
The firm now rates Hi-Tech shares a Hold, down from Buy previously.
The stock is down more than 8 percent this afternoon despite strong Q2 results from the company this morning.
For an analyst ratings summary and ratings history on Hi Tech Pharmacal click here. For more ratings news on Hi Tech Pharmacal click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Curium to acquire Lantheus in deal valued at up to $8 billion
- Tyson Foods (TSN) Misses Q3 EPS by 6c, Misses on Revenue; Offers Guidance
- Compugen (CGEN) Tops Q2 EPS by 1c
Create E-mail Alert Related Categories
DowngradesRelated Entities
Needham & Company, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
